SecBot

SecBot
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001707502

SLDB

Solid Biosciences Inc.
$6.91 ▼ -1.00%
Prev close $6.98
Market cap$775.2M
ConsensusStrong Buy
12-mo target$18.62 (+169.4%)
▲ Bullish
Analyst conviction 10/10
Insider Selling Cluster (7 insiders)High Impact Filing (7/10)34 New Institutional Positions11 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on SLDB right now — valuation, ownership and activity at a glance.
Market Cap
$775.2M
Cap Size
Small Cap
Analyst Consensus
Strong Buy (95%)
Inst. Holders
50 funds
Inst. Value
$671.8M
Inst. Activity
34 buys / 11 sells
Insider Activity
$0.00 buy / $2.3M sell
Insider Net $
-$2.3M
Social Sentiment
67° Warm
SEC Reports
6
Press Releases
5
Price chart 30d -32.8%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 other
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Co
Aug 6, 2026 SEC
Solid Biosciences filed an S-3ASR shelf registration statement, registering an unlimited amount of senior and subordinat
S-3ASR — Impact 4/10
Jul 2, 2026 Insider
SMITH IAN F acquired via exercise 3,440 shares
Director
Jun 30, 2026 Inst.
RA CAPITAL MANAGEMENT, L.P. — ADD
12,036,126 shares ($120.2M)
Jun 30, 2026 Inst.
BlackRock, Inc. — ADD
6,934,248 shares ($69.3M)
Jun 10, 2026 Insider
Stone Adam Leo was granted 77,500 shares
Director
Jun 10, 2026 Insider
Ganot Ilan was granted 77,500 shares
Director
May 12, 2026 SEC
Solid Biosciences reported Q1 2026 EPS of -$0.53, a 20.9% miss versus the -$0.44 consensus, with net loss widening to $5
PRESS-RELEASE — Impact 6/10
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Strong Buy 95% rate it Buy or better · 19 analysts
Strong Buy 8 42% Buy 10 53% Hold 1 5% Sell 0 0% Strong Sell 0 0%
Recent analyst actions
DateFirmActionRatingFirm rating
Sep 16, 2026RBC CapitalINITIATEOutperform 55%
Sep 14, 2026HC Wainwright & Co.REITERATEBuy 43%
Aug 27, 2026Cantor FitzgeraldMAINTAINOverweight 49%
Aug 21, 2026Truist SecuritiesMAINTAINBuy 55%
Jun 3, 2026HC Wainwright & Co.MAINTAINBuy 43%
May 18, 2026WedbushREITERATEOutperform 57%
May 13, 2026WedbushMAINTAINOutperform 57%
May 13, 2026Piper SandlerMAINTAINOverweight 54%
Monthly consensus history
PeriodStr. BuyBuyHoldSellStr. SellBuy %Distribution
Sep 1, 202681010095%
Aug 1, 202681010095%
Jul 1, 202681110095%
Jun 1, 202681110095%
May 1, 202681110095%
Apr 1, 202681110095%
Mar 1, 202671110095%
Feb 1, 202671110095%
Price targets
Where 13 covering analysts think SLDB trades over the next 12 months.
$18.62 +169.4% upside Strong Buy
Current$6.91 Low$11.00 Median$18.00 High$26.00 13 analysts
$11.00$26.00
Analyst rating Strong Buy· 1.4/5 as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
67°
Warm
BearishNeutralBullish
2 mentions 2 bullish 0 bearish 0 neutral
Recent posts
wallstreetbets Bullish 3mo ago
SLDB Solid Biosciences 4pm 3.4 M
▲ 1 · 💬 0· ⚡ 0.5
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
6 SEC filing reports analyzed · 1 bullish, 2 bearish, 0 mixed, 3 neutral · avg impact 5.0/10.Plus 5 press releases.
NEUTRALS-3ASR4/10
Solid Biosciences filed an S-3ASR shelf registration statement, registering an unlimited amount of s
Aug 6, 2026
BEARISHPRESS-RELEASE6/10
Solid Biosciences reported Q1 2026 EPS of -$0.53, a 20.9% miss versus the -$0.44 consensus, with net
May 12, 2026
NEUTRALDEFA14A3/10
Solid Biosciences is holding its 2026 annual meeting with several key proposals, including the ratif
Apr 23, 2026
NEUTRAL8-K2/10
Solid Biosciences Inc. announced a board seat reclassification for director Ilan Ganot, who resigned
Apr 10, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
other
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precis
Sep 24, 2026
short_volume
Short Volume: SLDB — 61.0% short (0.3M / 0.5M)
Short: 332,042 | Exempt: 11,683 | TRF Vol: 544,660 | Short Ratio: 61.0% | Off-exchange volume (dark pool + OTC)
Sep 22, 2026
short_volume
Short Volume: SLDB — 88.9% short (0.6M / 0.6M)
Short: 559,005 | Exempt: 0 | TRF Vol: 629,097 | Short Ratio: 88.9% | Off-exchange volume (dark pool + OTC)
Sep 16, 2026
short_volume
Short Volume: SLDB — 60.2% short (0.6M / 1.0M)
Short: 618,139 | Exempt: 501 | TRF Vol: 1,026,374 | Short Ratio: 60.2% | Off-exchange volume (dark pool + OTC)
Aug 10, 2026
earnings_calendar
SLDB Q2 2026 Earnings Scheduled — 2026-08-10
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
PeriodEPS Est.RangeGrowth30d RevUp/DnRevenue#
Current Q$-0.41$-0.53–$-0.3413.7%-0.4%8↑ 1↓$0.0B13
Next Q$-0.43$-0.54–$-0.3419.4%-0.5%9↑ 1↓$0.0B13
Current FY$-1.76$-2.39–$-1.5511.4%-0.2%12↑ 0↓$0.0B13
Next FY$-1.70$-2.40–$-1.303.4%+2.4%9↑ 2↓$0.0B13
Current-quarter EPS estimate — revision history
WhenEPS estimateChange vs now
Current$-0.414—
7d ago$-0.413-0.001
30d ago$-0.413-0.002
60d ago$-0.481+0.067
90d ago$-0.475+0.061
Institutional ownership
Which big funds own SLDB (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $671.8M total value (67,264,633 shares) as of 2026-Q2. Top holders: RA, BlackRock,, FMR. Net buying activity: 34 institutions added/increased vs 11 reduced.
Top holders — 2026-Q2
FundSharesValue% TrackedLast move
RA CAPITAL MANAGEMENT, L.P.12,036,126$120.2M17.9%ADD +28.9%
BlackRock, Inc.6,934,248$69.3M10.3%ADD +39.8%
FMR LLC6,875,957$68.7M10.2%ADD +90.7%
STATE STREET CORP4,175,365$41.7M6.2%DOUBLED +271.0%
Jupiter Topco LLC4,043,605$40.4M6.0%—
VANGUARD CAPITAL MANAGEMENT LLC4,009,922$40.1M6.0%ADD +49.9%
RTW INVESTMENTS, LP3,892,926$38.9M5.8%NEW
FRANKLIN RESOURCES INC3,440,708$34.4M5.1%—
CITADEL ADVISORS LLC2,815,122$28.1M4.2%—
Alyeska Investment Group, L.P.2,280,484$22.8M3.4%ADD +35.5%
Recent position changes
FundActionPrevCurrentChangeValue
RA CAPITAL MANAGEMENT, L.P.ADD9,339,97812,036,126+28.9%$120.2M
BlackRock, Inc.ADD4,958,3546,934,248+39.8%$69.3M
FMR LLCADD3,606,4046,875,957+90.7%$68.7M
STATE STREET CORPDOUBLED1,125,4874,175,365+271.0%$41.7M
VANGUARD CAPITAL MANAGEMENT LLCADD2,674,6244,009,922+49.9%$40.1M
RTW INVESTMENTS, LPNEW—3,892,926—$38.9M
GEODE CAPITAL MANAGEMENT, LLCADD1,295,9841,940,824+49.8%$19.4M
GOLDMAN SACHS GROUP INCADD935,5351,602,917+71.3%$16.0M
DIMENSIONAL FUND ADVISORS LPADD956,1351,266,290+32.4%$12.6M
VANGUARD PORTFOLIO MANAGEMENT LLCDOUBLED338,630748,589+121.1%$7.5M
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
15 insiders, 50 transactions. Net -$2.3M — $0.00 bought, $2.3M sold.
DateInsiderTitleTypeSharesPriceValue
Jul 2, 2026SMITH IAN FDirectorEXERCISE3,440——
Jun 10, 2026Stone Adam LeoDirectorAWARD77,500——
Jun 10, 2026Ganot IlanDirectorAWARD77,500——
Jun 10, 2026Keresty GeorgiaDirectorAWARD77,500——
Jun 10, 2026Kahn ClareDirectorAWARD77,500——
Jun 10, 2026Sullivan Lynne MarieDirectorAWARD77,500——
Jun 10, 2026PERCEPTIVE ADVISORS LLCDirectorAWARD77,500——
Jun 10, 2026Nagendran SukumarDirectorAWARD77,500——
Jun 10, 2026SMITH IAN FDirectorAWARD77,500——
Jun 10, 2026Freed Martin IDirectorAWARD77,500——
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for SLDB.
Shares short
17,106,152
Settlement Sep 15, 2026
Change vs prior
+4.4%
Semi-monthly cycle
Days to cover
19.6
At avg daily volume
Of shares outstanding
≈15.9%
Estimate — not % of float
All SLDB filing & press-release reports (11)